Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin.

@article{Greco2000CarcinomaOU,
  title={Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin.},
  author={Frank Anthony Greco and Joan B Erland and Lisa H Morrissey and Howard A. Burris and Robert C Hermann and Ronald G. Steis and Damien Thompson and James Richard Andrew Gray and John D Hainsworth},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2000},
  volume={11 2},
  pages={211-5}
}
PURPOSE To evaluate the toxicity, response rate and short-term survival associated with the chemotherapy combinations of docetaxel plus cisplatin or carboplatin when used for the treatment of patients with metastatic carcinoma of unknown primary site. PATIENTS AND METHODS Twenty-six patients were treated with docetaxel 75 mg/m2 i.v. and cisplatin 75 mg/m2 i.v. given every three weeks (study A) and subsequently, 47 patients were treated with docetaxel 65 mg/m2 and carboplatin (AUC dose = 6… CONTINUE READING